Association of schizophrenia onset age and white matter integrity with treatment effect of D-cycloserine: a randomized placebo-controlled double-blind crossover study

Autor: Naoki Yamamoto, Sayuri Ishiwata, Makoto Tomita, Toru Nishikawa, Kenji Narushima, Masahito Nakataki, Yasuyoshi Ishiwata, Kosaku Shoda, Akeo Kurumaji, Mai Tamaru, Akihito Uezato, Masato Yasuhara, Kunimasa Arima, Kazunari Oshima, Michio Itasaka, Tetsuro Ohmori, Kazuo Takiguchi, Mitsutoshi Okazaki, Hidenori Atsuta
Rok vydání: 2017
Předmět:
Adult
Male
medicine.medical_specialty
External capsule
lcsh:RC435-571
D-cycloserine
Randomized
Splenium
Corpus callosum
White matter
03 medical and health sciences
0302 clinical medicine
Double-Blind Method
lcsh:Psychiatry
Internal medicine
medicine
Humans
Cingulum (brain)
Age of Onset
Psychiatry
Scale for the Assessment of Negative Symptoms
MR diffusion tensor imaging
Cross-Over Studies
Positive and Negative Syndrome Scale
Double-blind
Glycine Agents
Middle Aged
Placebo-controlled
medicine.disease
White Matter
030227 psychiatry
Psychiatry and Mental health
Diffusion Tensor Imaging
medicine.anatomical_structure
Cycloserine
Schizophrenia
Crossover
Drug Therapy
Combination

Female
Schizophrenic Psychology
Glutamate
Psychology
030217 neurology & neurosurgery
Antipsychotic Agents
Research Article
Zdroj: BMC Psychiatry
BMC Psychiatry, Vol 17, Iss 1, Pp 1-15 (2017)
ISSN: 1471-244X
Popis: Background It has been reported that drugs which promote the N-Methyl-D-aspartate-type glutamate receptor function by stimulating the glycine modulatory site in the receptor improve negative symptoms and cognitive dysfunction in schizophrenia patients being treated with antipsychotic drugs. Methods We performed a placebo-controlled double-blind crossover study involving 41 schizophrenia patients in which D-cycloserine 50 mg/day was added-on, and the influence of the onset age and association with white matter integrity on MR diffusion tensor imaging were investigated for the first time. The patients were evaluated using the Positive and Negative Syndrome Scale (PANSS), Scale for the Assessment of Negative Symptoms (SANS), Brief Assessment of Cognition in Schizophrenia (BACS), and other scales. Results D-cycloserine did not improve positive or negative symptoms or cognitive dysfunction in schizophrenia. The investigation in consideration of the onset age suggests that D-cycloserine may aggravate negative symptoms of early-onset schizophrenia. The better treatment effect of D-cycloserine on BACS was observed when the white matter integrity of the sagittal stratum/ cingulum/fornix stria terminalis/genu of corpus callosum/external capsule was higher, and the better treatment effect on PANSS general psychopathology (PANSS-G) was observed when the white matter integrity of the splenium of corpus callosum was higher. In contrast, the better treatment effect of D-cycloserine on PANSS-G and SANS-IV were observed when the white matter integrity of the posterior thalamic radiation (left) was lower. Conclusion It was suggested that response to D-cycloserine is influenced by the onset age and white matter integrity. Trial registration UMIN Clinical Trials Registry (number UMIN000000468 ). Registered 18 August 2006
Databáze: OpenAIRE